- Why early de-risking is redefining the path to INDLonza explains why early de-risking has become a strategic imperative for biotech teams working to reach IND with confidence.Fierce Biotech · 9d ago↗ source
- Radiopharma maker AdvanCell hauls in $315M for Pluvicto challengerAdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment. The round marks one of the largest yet for a r…Endpoints · 9d ago↗ source
- STAT+: Celcuity’s breast cancer drug approved, its firstFDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The ReadoutSTAT · 9d ago↗ source